In 2021, Pfizer settled a Canadian class action case related to the bone density loss side effects and related conditions for over $2 million
His favorite is BPC-157
However, 7 cross sectional studies examining acute effects of the GLP-1-based therapies 37,38,39,40,41,42,43 found a significant increase in % FMD following GLP-1-based interventions (mean difference in the changes from baseline: 2.58 [1.68, 3.53] %
Each site has its own characteristics regarding comfort, accessibility, and absorption rate, and understanding these differences helps you make informed choices about where to inject for the best experience
SD: Resources, Data curation, Writing original draft